Panzyga
- Product NDC
- 0069-1224
- Type
- PLASMA DERIVATIVE
- Nonproprietary name
- immune globulin intravenous (human)
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Labeler
- Pfizer Laboratories Div Pfizer Inc
- Application
- BLA125587
- Marketing category
- BLA
- Substance
- HUMAN IMMUNOGLOBULIN G
- Current FDA listing
- Yes
Related Records
Packages
| Package NDC | Description | Marketing start | Marketing end | Sample | Status |
|---|---|---|---|---|---|
| 0069-1224-02 | 1 BOTTLE, GLASS in 1 CARTON (0069-1224-02) / 50 mL in 1 BOTTLE, GLASS (0069-1224-01) | 2019-08-09 | No | Historical |
Related DailyMed Labels
| Title | Manufacturer | Effective date | Type | Version |
|---|---|---|---|---|
| These highlights do not include all the information needed to use PANZYGA safely and effectively. See full prescribing information for PANZYGA. PANZYGA, (immune globulin intravenous, human - ifas) 10% Liquid Preparation Initial U.S. Approval: 2018 | Pfizer Laboratories Div Pfizer Inc | 2025-05-08 | PLASMA DERIVATIVE | 10 |